Brief: ANI Pharmaceuticals Q3 Adjusted EPS USD 2.04 Vs. IBES Estimate USD 1.75
07/11/2025 11:50
Nov 07 (Reuters) - ANI Pharmaceuticals Q3 EPS USD 1.13. Q3 net income USD 26.3 million Q3 revenue USD 227.8 million vs. IBES estimate USD 211 million Q3 adjusted EBITDA USD 59.6 million outlook FY revenue USD 854-873 million outlook FY adjusted EBITDA USD 221-228 million outlook FY adjusted EPS USD 7.37-7.64
Recent news on ANI Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
ANI Pharmaceuticals Q1 revenue rises 21%, adjusted EPS beats estimates
Brief: ANI Pharmaceuticals Q1 Adjusted EPS USD 2.05 Vs. IBES Estimate USD 1.3
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma